Winfield Associates’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Winfield Associates’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-500	Closed	-$3K	–	712
2017 Q4	$3K	Hold	500	–	–	﹤0.01%	623
2017 Q3	$2K	Hold	500	–	–	﹤0.01%	640
2017 Q2	$1K	Hold	500	–	–	﹤0.01%	832
2017 Q1	$1K	Hold	500	–	–	﹤0.01%	714
2016 Q4	$1K	Hold	500	–	–	﹤0.01%	687
2016 Q3	$1K	Hold	500	–	–	﹤0.01%	659
2016 Q2	$1K	Hold	500	–	–	﹤0.01%	668
2016 Q1	$1K	Hold	500	–	–	﹤0.01%	657
2015 Q4	$2K	Sell	500 -286	-36%	-$1.15K	﹤0.01%	293
2015 Q3	$3K	Hold	786	–	–	﹤0.01%	283
2015 Q2	$3K	Hold	786	–	–	﹤0.01%	273
2015 Q1	$3K	Hold	786	–	–	﹤0.01%	279
2014 Q4	$4K	Hold	786	–	–	﹤0.01%	276
2014 Q3	$7K	Hold	786	–	–	0.01%	251
2014 Q2	$7K	Hold	786	–	–	0.01%	261
2014 Q1	$11K	Hold	786	–	–	0.01%	235
2013 Q4	$18K	Buy	+786	New	+$21.4K	0.01%	217

Other funds holding STAB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Winfield Associates's STAB Position: Q1 2018 in Review

Winfield Associates sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2018, closing a stake of 500 shares — an estimated $3K sold.

Winfield Associates first reported a position in STAB in Q4 2013 and held it in 17 quarters. The position peaked at $18K in Q4 2013. 16 funds tracked by Wall St. Rank hold STAB as of Q1 2018.

Winfield Associates reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Winfield Associates sold 500 Statera Biopharma, Inc. Common Stock shares in Q1 2018, an estimated $3K.
Winfield Associates first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2013 and held it in 17 quarters.
Winfield Associates's Statera Biopharma, Inc. Common Stock position peaked at $18K in Q4 2013.
16 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.